IMGT (XKRX:456570) Equity-to-Asset : -1.60 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is IMGT Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. IMGT's Total Stockholders Equity for the quarter that ended in Dec. 2023 was ₩-16,857.41 Mil. IMGT's Total Assets for the quarter that ended in Dec. 2023 was ₩10,559.77 Mil. Therefore, IMGT's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was -1.60.

The historical rank and industry rank for IMGT's Equity-to-Asset or its related term are showing as below:

XKRX:456570' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.77 Med: -1.49 Max: -1.2
Current: -1.6

During the past 4 years, the highest Equity to Asset Ratio of IMGT was -1.20. The lowest was -1.77. And the median was -1.49.

XKRX:456570's Equity-to-Asset is ranked worse than
93.91% of 1559 companies
in the Biotechnology industry
Industry Median: 0.67 vs XKRX:456570: -1.60

IMGT Equity-to-Asset Historical Data

The historical data trend for IMGT's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IMGT Equity-to-Asset Chart

IMGT Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

-1.20

-1.39

-1.77

-1.60

IMGT Semi-Annual Data
	Dec20	Dec21	Dec22	Dec23
Equity-to-Asset	-1.20	-1.39	-1.77	-1.60

Competitive Comparison of IMGT's Equity-to-Asset

For the Biotechnology subindustry, IMGT's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IMGT's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IMGT's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where IMGT's Equity-to-Asset falls into.

IMGT Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

IMGT's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	-16857.411	/	10559.766
	=	-1.60

IMGT's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	-16857.411	/	10559.766
	=	-1.60

IMGT (XKRX:456570) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

IMGT Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of IMGT's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

IMGT (XKRX:456570) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IMGT Corp Ltd (XKRX:456570) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

172 Dolma-ro,, 408, Healthcare Innovation Park, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13605

Website

http://www.imgt.co.kr

IMGT Corp Ltd develops a focused ultrasound-based drug delivery platform for intractable diseases. It is developing nanomedicines and focused ultrasound medical devices that respond to focused ultrasound. The firm has two pipeline products IMD20 and IMP101. IMD20 is a FUS device developed for chronic pain as a product with reduced size and output from IMD10 developed for cancer treatment. IMP101 is a nanoparticle used for hepatocarcinoma embolization.

IMGT (XKRX:456570) Headlines

No Headlines